Enlivex Therapeutics Ltd (ENLV)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.82M
Last updated: Nov 17, 2026 at 11:04 AM ET
Enlivex Therapeutics Ltd (ENLV) Financials: Revenue, Profit and Cash Flow
Enlivex Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was $1.24B, operating cash flow was -$10.42M and free cash flow was -$10.48M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of $1.89B.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $15.00M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | N/A | N/A | N/A | N/A |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2020 | $2.28M | N/A | -12.6% | -429.7% | -519.3% |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2016 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Jun 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $2.28M | $0 | $0 | $0 | $0 |
| Cost of revenue | $332.00K | $545.00K | $835.00K | $777.00K | $546.00K | $286.00K | $297.00K | $121.00K | $12.00K | $25.00K |
| Gross profit | -$332.00K | -$545.00K | -$835.00K | -$777.00K | -$546.00K | -$286.00K | -$297.00K | -$121.00K | -$12.00K | -$25.00K |
| Research and development | $8.92M | $10.13M | $19.23M | $18.69M | $12.88M | $6.09M | $5.72M | $4.13M | $2.52M | $8.88M |
| Operating income | -$15.00M | -$15.54M | -$29.39M | -$25.80M | -$19.29M | -$9.79M | -$8.62M | -$5.30M | -$5.85M | -$13.95M |
| Net income | $1.24B | -$15.01M | -$29.07M | -$31.06M | -$14.47M | -$11.82M | -$9.38M | -$4.24M | -$5.95M | -$16.02M |
| EBITDA | -$14.67M | -$14.47M | -$28.22M | -$25.02M | -$18.74M | -$9.50M | -$8.41M | -$5.18M | N/A | -$13.92M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit | -$57.00K | N/A | -$76.00K | -$81.00K | -$85.00K | -$90.00K | -$36.00K | -$161.00K | -$160.00K | -$188.00K | -$200.00K | -$214.00K |
| Operating income | -$4.23M | -$7.91M | -$5.86M | -$2.56M | -$3.08M | -$3.53M | -$5.63M | -$3.12M | -$2.99M | -$3.95M | -$6.09M | -$5.63M |
| Net income | $1.89B | $974.52M | $1.24B | -$2.21M | -$1.87M | -$3.45M | -$5.18M | -$2.60M | -$3.10M | -$4.14M | -$9.10M | -$5.96M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $258.00K by $1.75M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.33B | $27.69M | $36.83M | $67.64M | $95.15M | $40.36M | $17.56M | $11.03M | $3.62M | $10.63M |
| Current assets | $1.74B | $25.99M | $33.76M | $52.33M | $86.44M | $38.12M | $16.42M | $10.28M | $3.62M | $10.54M |
| Cash and equivalents | $2.01M | $3.30M | $813.00K | $49.95M | $11.20M | $5.67M | $3.95M | $9.74M | $3.53M | $6.87M |
| Total liabilities | $392.05M | $4.10M | $6.75M | $10.80M | $10.11M | $4.87M | $6.28M | $1.33M | $460.00K | $1.93M |
| Short-term debt | $258.00K | $235.00K | $346.00K | $653.00K | $617.00K | $203.00K | $123.00K | N/A | N/A | N/A |
| Shareholder equity | $1.93B | $23.59M | $30.08M | $56.84M | $85.04M | $35.49M | $11.28M | $9.71M | $3.16M | $8.70M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $4.90B | N/A | $2.33B | $20.94M | $22.60M | $24.04M | $27.69M | $29.80M | $31.90M | $31.05M | $36.83M | $46.94M |
| Total liabilities | $1.00B | -$1.93B | $392.05M | $3.46M | $3.54M | $3.41M | $4.10M | $3.21M | $3.34M | $4.20M | $6.75M | $8.16M |
| Cash and equivalents | $5.52M | N/A | $2.01M | $4.20M | $1.89M | $2.05M | $3.30M | $2.77M | $3.75M | $2.03M | $926.00K | $1.97M |
| Shareholder equity | $3.90B | $1.93B | $1.93B | $17.48M | $19.05M | $20.63M | $23.59M | $26.59M | $28.56M | $26.85M | $30.08M | $38.78M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.42M | -$13.01M | -$23.52M | -$23.95M | -$17.54M | -$11.01M | -$7.04M | -$3.16M | -$6.35M | -$15.49M |
| Capital expenditures | $68.00K | $103.00K | $236.00K | $8.12M | $1.63M | $1.02M | $193.00K | $461.00K | $2.00K | $18.00K |
| Free cash flow | -$10.48M | -$13.11M | -$23.76M | -$32.08M | -$19.17M | -$12.03M | -$7.23M | -$3.62M | -$6.35M | -$15.50M |
| Investing cash flow | -$1.32M | $9.06M | -$25.97M | $62.52M | -$38.41M | -$20.98M | -$6.36M | -$533.00K | $3.01M | $8.98M |
| Financing cash flow | $10.38M | $6.45M | $360.00K | $150.00K | $60.98M | $33.08M | $8.31M | $5.19M | $8.05M | $6.09M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.47M | -$5.47M | -$2.90M | -$1.97M | -$1.20M | -$4.62M | -$4.08M | -$2.62M | -$1.80M | -$4.51M | -$5.03M | -$5.44M |
| Capital expenditures | $4.50K | $4.50K | $9.38K | $23.55K | $7.00K | $32.00K | $35.00K | $9.00K | $16.00K | $43.00K | N/A | $29.00K |
| Free cash flow | -$5.47M | -$5.47M | -$2.91M | -$1.99M | -$1.21M | -$4.66M | -$4.12M | -$2.63M | -$1.81M | -$4.55M | N/A | -$5.47M |
Frequently Asked Questions About ENLV
What is Enlivex Therapeutics' annual revenue?
Enlivex Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.
Is Enlivex Therapeutics profitable?
Yes. Enlivex Therapeutics reported net income of $1.24B for the fiscal year ended Dec 31, 2025.
How much free cash flow does ENLV generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$10.42M minus capital expenditures of $68.00K produced free cash flow of -$10.48M.
How much debt does Enlivex Therapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $258.00K and cash and equivalents of $2.01M.
ENLV pages: Overview, Earnings, Forecast, Financials, Competitors